Arbutus Biopharma Corporation与Genevant Sciences已在加拿大联邦法院提起诉讼，指控辉瑞与BioNTech SE侵犯其脂质纳米颗粒技术专利。该诉讼寻求法院颁布禁令，以阻止被告方继续使用相关专利技术，并要求其就侵权行为支付损害赔偿。
诉状指出，辉瑞与BioNTech未经授权，在其新冠疫苗中使用了Arbutus和Genevant拥有的专有LNP递送技术。原告方主张，被告的侵权行为已对其业务造成重大损害，并寻求通过法律途径获得救济。
此次诉讼是Arbutus围绕其LNP知识产权发起的系列法律行动之一。该技术被视为mRNA疫苗和疗法的关键递送系统，具有重要的商业价值。案件的进展预计将受到生物技术及制药行业的密切关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.